Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Catherine Longworth
Quanta Dialysis has signed an agreement with B. Braun to provide support services to Quanta’s patients in the UK. The hemodialysis firm launched its compact hemodialysis device SC+ on the market at the beginning of the year.
San Francisco-based start-up Steady Health is launching the first virtual full-service endocrinology clinic in California.
Roche and Illumina have entered a 15-year, non-exclusive partnership to expand access to next-generation sequencing- based testing in cancer care.
Laborie Medical Technologies has inked a $525m deal to buy obstetrics device maker Clinical Innovations. The acquisition adds a suite of neonatal and fetal care devices to Laborie’s existing obstetrics portfolio.
Johnson & Johnson is acquiring the remaining stake in Verb Surgical from Verily following a four-year partnership. The transaction is expected to close in the first half of 2020.
Guerbet announced its chief commercial officer will take over as CEO in January 2020. David Hale will lead the imaging company as it steps up its growth strategy, called Gear 2023.